Mexazolam
150px | |
150px | |
Systematic (IUPAC) name | |
---|---|
10-chloro- 11b-(2-chlorophenyl)- 3-methyl- 2,3,7,11b-tetrahydro [1,3]oxazolo [3,2-d] [1,4]benzodiazepin- 6(5H)-one | |
Clinical data | |
Pregnancy category |
|
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | Hepatic |
Biological half-life | ? |
Excretion | Renal |
Identifiers | |
ATC code | none |
PubChem | CID 4177 |
Synonyms | 13-chloro- 2-(2-chlorophenyl)- 5-methyl- 3-oxa- 6,9-diazatricyclo[8.4.0.02,6] tetradeca- 1(10),11,13-trien- 8-one |
Chemical data | |
Formula | C18H16Cl2N2O2 |
Molar mass | 363.237 g/mol[[Script error: No such module "String".]] |
Mexazolam (marketed under brand name Melex and Sedoxil)[1] is a drug which is a benzodiazepine derivative.[2] Atorvastatin administration along with mexazolam results in a reduced elimination rate of mexazolam.[3] Mexazolam has been trialed for anxiety and was found to be effective in alleviating anxiety at one week follow-up, however, after three weeks of therapy mexazolam had lost its therapeutic anxiolytic properties becoming no more effective than placebo, presumably due to benzodiazepine tolerance.[4] Mexazolam is metabolised via thee CYP3A4 pathway. HMG-CoA reductase inhibitors including simvastatin, simvastatin acid, lovastatin, fluvastatin, atorvastatin and cerivastatin inhibit the metabolism of mexazolam. Pravastatin, an HMG-CoA reductase inhibitor however, does not inhibit mexazolam metabolism.[5][6]
See also
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
This pharmacology-related article is a stub. You can help ssf by expanding it. |
- ↑ "Benzodiazepine Names". non-benzodiazepines.org.uk. Retrieved 2009-04-05.
- ↑ Kurono, Y; Kamiya, K; Kuwayama, T; Jinno, Y; Yashiro, T; Ikeda, K (1987). "Kinetics and mechanism of the acid-base equilibrium of mexazolam and comparison with those of other commercial benzodiazepinooxazole drugs". Chemical & pharmaceutical bulletin. 35 (9): 3831–7. PMID 2893667.
- ↑ Mc Donnell, CG; Harte, S; O'driscoll, J; O'loughlin, C; Van Pelt, FN; Shorten, GD (2003). "The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam". Anaesthesia. 58 (9): 899–904. doi:10.1046/j.1365-2044.2003.03339.x. PMID 12911366.
- ↑ Ferreira, L; Figueira, ML; Bessa-Peixoto, A; Marieiro, A; Albuquerque, R; Paz, C; Cerqueira, A; Damião, P; Dolgner, A (2003). "Psychomotor and anxiolytic effects of mexazolam in patients with generalised anxiety disorder". Clinical drug investigation. 23 (4): 235–43. doi:10.2165/00044011-200323040-00003. PMID 17535036.
- ↑ Ishigami, M; Takasaki, W; Ikeda, T; Komai, T; Ito, K; Sugiyama, Y (2002). "Sex difference in inhibition of in vitro mexazolam metabolism by various 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in rat liver microsomes". Drug metabolism and disposition: the biological fate of chemicals. 30 (8): 904–10. doi:10.1124/dmd.30.8.904. PMID 12124308.
- ↑ Ishigami, Michi; Honda, Tomoyo; Takasaki, Wataru; Ikeda, Toshihiko; Komai, Toru; Ito, Kiyomi; Sugiyama, Yuichi (2001). "A Comparison of the Effects of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors on the CYP3A4-Dependent Oxidation of Mexazolam in Vitro". Drug Metabolism and Disposition. 29 (3): 282. PMID 11181496.
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Benzodiazepines
- Organochlorides
- Lactams
- Oxazolobenzodiazepines
- Pharmacology stubs
- 2Fix